PMV Pharmaceuticals, Inc.

Today, we spotlight our field medical team, strategically located across the U.S., Europe, and Asia-Pacific. Our Medical Science Liaison (MSL) colleagues play a crucial role in the development of PMV’s therapies targeting p53. This involves collaborating closely with clinical trial sites, connecting our study data and clinical practice in oncology, and advocating our mission to develop meaningful outcomes for patients living with cancer. Swipe below to learn more about our talented MSL colleagues - Holly Nguyen, PhD, Kelly Kreitzburg Ondrasek, PhD, Olivia Goss, PharmD, Omar Mezghrani PharmD, PhD, and Leia Hee - and discover their unique expertise and motivations that drive them to make a difference in the fight against cancer. #Oncology #MedicalScienceLiaisons #PMVPharma #HealthcareInnovation #PatientCare

We are excited to announce that Diana McClellan joins our team as Associate Director of GMP Quality Assurance. With more than 25 years in QA leadership, Diana has experience managing contract manufacturing, technical transfer, and product launches. Her expertise encompasses cell and gene therapy, oncology, sterile pharmaceuticals, biologics, and medical devices. Diana excels in ensuring regulatory and cGMP compliance, improving quality systems, and driving efficiency. She has held key QA positions at Bristol Myers Squibb, Rocket Pharmaceuticals, Sandoz, and Antares Pharma. Please join us in welcoming Diana!

We’re excited to announce Dr. Weihong Zhang joins us as our new Director of CMC! Dr. Zhang earned her PhD in Organic Chemistry from Rutgers University and completed her postdoctoral research at Yale University.   With more than 20 years of experience at Celgene, Weihong has made significant contributions as a discovery chemist, where she invented several drug candidates. She then transitioned to a process chemist role, successfully leading a drug substance development project from early-stage (Tox and FIH batches) to late-stage (commercial routes, process validation).   Weihong’s extensive industrial experience will be invaluable to PMV as we advance rezatapopt towards commercialization and expand our pipeline. Let’s warmly welcome Weihong to our team!

A diagnosis of ovarian cancer can feel overwhelming. However, understanding genetic and biomarker tumor testing can help. Today, your treatment plan can be tailored to you using these tests (1). They offer vital information about your cancer, guiding your healthcare team in selecting effective therapies or possibly leading to participation in clinical trials. #OvarianCancer #CancerResearch #BiotechInnovation #OncologyResearch #P53 (1) Atallah GA, et al. Diagnostics (Basel). 2021;11(3):465. MA-586-0062 March 2025 

Did you know that the p53 protein, often called the "guardian of the genome," is a critical player in preventing cancer? It monitors our cells for DNA damage and initiates processes that help to protect against cancer. Mutations in the TP53 gene occur in more than 50% of cancers, resulting in the loss of these protective mechanisms. Restoring p53’s activity has the potential to transform cancer treatment and prevention strategies.    A recent article in ACS Medicinal Chemistry Letter describes the chemistry efforts that led to the discovery and development of rezatapopt (also known as PC14586), our investigational small-molecule targeted treatment designed to reactivate the mutant p53 protein, specifically the Y220C variant.    For highlights, please swipe below, or click the link for the full paper: https://lnkd.in/gSdJry4u   Sources: 🔎 Wang H, et al. Signal Transduct Target Ther. 2023;8:92.   🔎 Park J-H, et al. FEBS Lett. 2016;590:924-34.   🔎 Ozaki T, et al. Cancers (Basel). 2011;3:994-1013.   🔎 Marei HE, et al. Cancer Cell Int. 2021;21:703. MA-586-0053 #PrecisionOncology #CancerResearch #BiotechInnovation #OncologyResearch #P53

Did you know that the p53 protein is a critical tumor suppressor in our bodies? Unfortunately, mutations in the p53 protein lead to a loss of its normal function. PMV's approach focuses on restoring this crucial protein function. Learn more about the science of p53: https://lnkd.in/gx_qf_Bt #PrecisionOncology #CancerResearch #BiotechInnovation #OncologyResearch #P53 

Please join us in welcoming Julia Dunn to our team as a Senior Clinical Trial Associate! Julia brings over 5 years of experience managing complex preclinical and early-phase oncology programs. She is known for her collaborative approach and strong communication skills, working closely with teams to ensure smooth and efficient trial execution. Previously, Julia worked as a Clinical Trial/Project Manager at Hotspot Therapeutics and before that held various roles in Global Project Management at Takeda Pharmaceutical. Julia is based in Cambridge, MA. We are thrilled to have her join us and look forward to her valuable contributions!

Join PMV Pharma at the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer (SGO), March 14-17, in Seattle. Poster presentation details:   📌 The PYNNACLE Phase 2 trial assessing the investigational drug rezatapopt (PC14586), a selective p53 reactivator, in patients with locally advanced or metastatic solid tumors (including ovarian and endometrial cancers) harboring a TP53 Y220C mutation   📌 Ecaterina E Dumbrava, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, USA   📌 Sunday, March 16 | 8:15 - 8:45am and 2:10-3:00pm PDT | Exhibit Hall 4AB   #SGOMtg #SGO2025 #PMVPharma #Cancer #Oncology #PrecisionOncology #CancerResearch #LifeSciences #Biotechnology 

A recent article published in ACS Division of Medicinal Chemistry Letter discusses the chemistry behind the discovery and development of rezatapopt (also known as PC14586), our investigational small-molecule targeted therapy aimed at reactivating the mutant p53 Y220C protein, which is present in various cancers including ovarian, lung, breast and endometrial cancers.     The discovery of rezatapopt was made possible through structure-based drug design and the incorporation of fluorine substitution. In mouse models with established human tumor xenografts harboring the p53 Y220C mutation, rezatapopt showed tumor inhibition and regression at well-tolerated doses. Phase 1 clinical trials have indicated that rezatapopt has a favorable safety profile and preliminary single-agent efficacy in heavily pre-treated patients across various solid tumor types harboring the TP53 Y220C mutation.     For those interested in following advancements in targeted cancer therapies, please follow the link to read the full paper: https://lnkd.in/gSdJry4u MA-586-0053  #PrecisionOncology #CancerResearch #BiotechInnovation #OncologyResearch #P53 

📢 Join PMV Pharma at the Australian Precision Oncology Symposium 2025 (APOS).   Oral Presentation:   📌 Title: Results from the Phase 1 Part of the PYNNACLE Study Assessing Rezatapopt in Patients with Advanced Solid Tumors Harboring a TP53 Y220C Mutation 📌 Presenter: Amy Body, BSc (Med) MBBS FRACP, Monash Medical Centre, Clayton, VIC, Australia 📌 Date and time: Friday, March 7, 2025, Session 1 from 1:00-2:45 pm AEDT; presentation from 1:45-2:05 pm AEDT   #PMVPharma #Cancer #Oncology #PrecisionOncology #CancerResearch #LifeSciences #Biotechnology